Showing now | Science


DNA Testing Company 23andMe Makes Nasdaq Debut

Consumer genetic testing company 23andMe has made its Nasdaq debut at about $11 a share. CEO Anne Wojcicki joined Cheddar to talk about taking the company public through a SPAC merger. The pandemic changing how the consumer viewed health and diagnostic testing and the company’s ongoing partnership with UK-based pharmaceutical company GSK made it the perfect time to launch an IPO, according to Wojcicki. She also noted that the company was able to do a great deal of research on users volunteering information, including on the genetic link between people who lose their sense of taste and smell when contracting COVID-19.

Up next